Idiopathic Pulmonary Fibrosis
Information
- Disease name
- Idiopathic Pulmonary Fibrosis
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05313672 | Active, not recruiting | Inspiratory Effort and Respiratory Mechanics in Spontaneously Breathing Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Matched Control Study | August 1, 2016 | August 1, 2026 | |
| NCT02951416 | Active, not recruiting | Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank | September 2009 | January 2040 | |
| NCT02755441 | Active, not recruiting | Pulmonary Fibrosis Biomarker Cohort - a Prospective Cohort of Incident Patients With IPF | April 2016 | December 2028 | |
| NCT05185089 | Active, not recruiting | Phase 2 | Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis | August 1, 2022 | June 2024 |
| NCT04643769 | Active, not recruiting | Phase 1 | Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | February 9, 2021 | December 30, 2024 |
| NCT05032066 | Active, not recruiting | Phase 2 | A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis | August 25, 2021 | July 2025 |
| NCT02772549 | Active, not recruiting | Early Diagnosis of Pulmonary Fibrosis - Diagnostic Delay | March 2016 | December 2028 | |
| NCT04300920 | Active, not recruiting | Phase 3 | Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial | December 17, 2020 | December 31, 2025 |
| NCT03457935 | Active, not recruiting | Detection of Early Idiopathic Pulmonary Fibrosis | April 10, 2018 | December 31, 2024 | |
| NCT04572958 | Active, not recruiting | Changes in iOS in IPF | November 6, 2020 | May 2027 | |
| NCT02407431 | Active, not recruiting | PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort | March 2015 | July 2025 | |
| NCT05513950 | Active, not recruiting | Phase 1 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF | January 25, 2023 | June 25, 2024 |
| NCT05497284 | Active, not recruiting | Phase 2 | To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF | November 10, 2022 | November 22, 2024 |
| NCT04312594 | Active, not recruiting | Phase 2 | Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis | September 8, 2020 | December 31, 2024 |
| NCT05028894 | Active, not recruiting | 23andMe IPF Research Study | June 5, 2020 | December 1, 2023 | |
| NCT03747627 | Active, not recruiting | BPF Genetics of ILD Study | January 19, 2019 | January 1, 2028 | |
| NCT04071769 | Active, not recruiting | Phase 2 | Genentech Xenon MRI Idiopathic Pulmonary Fibrosis | August 3, 2020 | August 30, 2024 |
| NCT05321420 | Active, not recruiting | Phase 2 | LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | July 29, 2022 | August 2025 |
| NCT04614441 | Active, not recruiting | NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib | December 25, 2020 | July 13, 2025 | |
| NCT05321069 | Active, not recruiting | Phase 3 | A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) | September 19, 2022 | November 15, 2024 |
| NCT05984992 | Active, not recruiting | Phase 1 | The First-in-human Study of SRN-001 in Healthy Participants | September 8, 2023 | August 15, 2024 |
| NCT02141087 | Approved for marketing | Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone | |||
| NCT02171156 | Approved for marketing | Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP) | |||
| NCT00692796 | Completed | N/A | Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis | April 2008 | March 2010 |
| NCT00705133 | Completed | Phase 2 | Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension | July 2008 | April 2011 |
| NCT06135363 | Completed | Phase 1 | Safety, Tolerability and Pharmacokinetic Study of SC1011 in Healthy Subjects | August 11, 2022 | January 14, 2023 |
| NCT00815711 | Completed | Idiopathic Pulmonary Fibrosis Registry for Future Studies | December 1, 2008 | June 10, 2015 | |
| NCT00903331 | Completed | Phase 2 | Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study | May 2009 | August 2011 |
| NCT01071707 | Completed | Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF) | December 2009 | August 2012 | |
| NCT00074698 | Completed | Phase 1 | Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis | December 8, 2003 | May 2004 |
| NCT01107028 | Completed | Beneficial Effects of Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis | February 2010 | October 2014 | |
| NCT01110694 | Completed | Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study | September 2010 | September 2018 | |
| NCT01118221 | Completed | N/A | Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients | October 2010 | September 2013 |
| NCT01134822 | Completed | Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England) | July 2010 | September 5, 2017 | |
| NCT01136174 | Completed | Phase 2 | Safety and PK Study of BIBF 1120 in Japanese Patients With IPF | May 2010 | |
| NCT01150591 | Completed | Microaspiration in Pulmonary Fibrosis | December 2009 | June 2015 | |
| NCT01199887 | Completed | Phase 1 | Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis | September 2010 | October 2012 |
| NCT01214187 | Completed | Phase 2 | Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis | July 2011 | April 2015 |
| NCT01254409 | Completed | Phase 1 | A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | March 29, 2011 | July 2, 2012 |
| NCT01262001 | Completed | Phase 2 | Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis | March 2011 | June 21, 2017 |
| NCT01265888 | Completed | Phase 2 | Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. | March 2011 | September 2016 |
| NCT05976217 | Completed | Early Phase 1 | Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis | October 1, 2023 | March 20, 2024 |
| NCT05870956 | Completed | Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients | May 16, 2023 | June 30, 2023 | |
| NCT01362231 | Completed | Phase 1 | A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis | December 2010 | December 2012 |
| NCT01366209 | Completed | Phase 3 | Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) | June 2011 | February 2014 |
| NCT05817240 | Completed | Phase 1 | A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects | May 3, 2023 | June 21, 2023 |
| NCT01385644 | Completed | Phase 1 | A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis | October 2010 | May 2013 |
| NCT01457261 | Completed | Phase 1 | IPF Drug Deposition Study | April 2012 | November 2014 |
| NCT01462006 | Completed | N/A | Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF) | October 2011 | March 2016 |
| NCT05784207 | Completed | An In Silico Trial to Evaluate Prospectively the Performance of a Radiomics Algorithm for UIP Compared to Medical Doctors | June 1, 2017 | December 30, 2021 | |
| NCT05779007 | Completed | Dose Reduction and Discontinuation With Anti-Fibrotic Medications | April 18, 2023 | July 14, 2023 | |
| NCT01529853 | Completed | Phase 1/Phase 2 | To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF) | January 2012 | October 2013 |
| NCT01619085 | Completed | Phase 3 | Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis | June 6, 2012 | February 1, 2021 |
| NCT05657184 | Completed | Phase 1/Phase 2 | Treatment of Idiopathic Pulmonary Fibrosis(IPF) by REGEND001 | July 19, 2021 | June 9, 2023 |
| NCT01637831 | Completed | N/A | CPAP Therapy in Patients With Idiopathic Pulmonary Fibrosis and Sleep Apnea | March 2010 | September 2011 |
| NCT01695408 | Completed | Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis | October 2012 | December 31, 2021 | |
| NCT05621252 | Completed | Phase 2 | Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809) | July 13, 2022 | January 8, 2024 |
| NCT01725139 | Completed | Phase 1 | A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | March 8, 2013 | July 12, 2016 |
| NCT01766817 | Completed | Phase 2 | Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis | January 31, 2013 | February 29, 2016 |
| NCT05428150 | Completed | Phase 1 | Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers | August 8, 2022 | September 25, 2022 |
| NCT01772667 | Completed | N/A | Long Term Effects of an Inpatient Pulmonary Rehabilitation Program in Patients With Pulmonary Fibrosis | October 2013 | October 2016 |
| NCT01777373 | Completed | Conducting Airways in Lung Fibrosis (VACFI) | August 2012 | February 2015 | |
| NCT05427253 | Completed | Phase 1 | First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects | June 15, 2022 | June 22, 2023 |
| NCT01817686 | Completed | N/A | Study of Default Options in Advance Directives | March 2013 | June 2015 |
| NCT05383131 | Completed | Phase 1 | To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers | June 23, 2021 | November 30, 2021 |
| NCT01872689 | Completed | Phase 2 | A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | October 13, 2013 | November 6, 2017 |
| NCT01874223 | Completed | Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With IPF | June 2013 | November 4, 2018 | |
| NCT01890265 | Completed | Phase 2 | Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) | July 30, 2013 | November 16, 2017 |
| NCT01919827 | Completed | Phase 1 | Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis | March 2013 | May 1, 2018 |
| NCT01979952 | Completed | Phase 3 | Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | November 26, 2013 | October 27, 2016 |
| NCT01982968 | Completed | N/A | Treatment of IPF With Laparoscopic Anti-Reflux Surgery | December 2013 | November 2017 |
| NCT02009293 | Completed | The Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary Fibrosis | December 2013 | December 2016 | |
| NCT02019641 | Completed | N/A | The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease | May 23, 2015 | May 24, 2023 |
| NCT02036580 | Completed | Phase 2 | D2212C00002 J-Phase II Study | January 2014 | November 2015 |
| NCT02036970 | Completed | Phase 2 | Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT | May 31, 2014 | May 16, 2018 |
| NCT02048644 | Completed | Phase 2 | Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis | March 2014 | May 2015 |
| NCT05353556 | Completed | N/A | Effects of Home-based Inspiratory Muscle Training in Patients With IPF | February 21, 2022 | May 30, 2022 |
| NCT02055456 | Completed | Phase 1/Phase 2 | Nandrolone Decanoate in the Treatment of Telomeropathies | February 1, 2014 | February 1, 2017 |
| NCT02058602 | Completed | Phase 1 | Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients | December 3, 2013 | July 11, 2016 |
| NCT02085018 | Completed | Phase 2 | Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF) | March 28, 2014 | September 27, 2016 |
| NCT02136992 | Completed | Phase 2 | Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | December 2011 | December 2013 |
| NCT02173145 | Completed | N/A | Azithromycin in Idiopathic Pulmonary Fibrosis | August 19, 2014 | August 16, 2019 |
| NCT04016168 | Completed | Idiopathic Pulmonary Fibrosis and Serum Bank | October 22, 2014 | December 28, 2022 | |
| NCT04396756 | Completed | Phase 2 | Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis | March 3, 2020 | February 15, 2023 |
| NCT04030026 | Completed | Phase 2 | A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough | August 8, 2019 | May 27, 2022 |
| NCT04031690 | Completed | Health and Quality of Life Assessment Project for Caregivers of Idiopathic Pulmonary Fibrosis Patients | October 14, 2019 | December 15, 2021 | |
| NCT04072315 | Completed | Phase 2 | Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/ | February 13, 2020 | July 5, 2022 |
| NCT00287716 | Completed | Phase 3 | Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | July 14, 2006 | November 10, 2008 |
| NCT04177251 | Completed | Cardiovascular Fibrosis in Idiopathic Pulmonary Fibrosis | October 21, 2019 | October 15, 2022 | |
| NCT04187079 | Completed | Immunopathologic Profiles and Blood Biomarkers in Patients With IPF | September 18, 2017 | July 27, 2021 | |
| NCT00287729 | Completed | Phase 3 | Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | April 2006 | November 2008 |
| NCT04318704 | Completed | Phase 2 | Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough | July 29, 2020 | May 10, 2022 |
| NCT04233814 | Completed | Phase 1 | Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects | January 20, 2020 | December 23, 2021 |
| NCT04316780 | Completed | Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes | April 15, 2019 | March 1, 2020 | |
| NCT00047658 | Completed | Phase 2 | A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF) | November 2001 | May 2003 |
| NCT00391443 | Completed | Phase 3 | BUILD 3: Bosentan Use in Interstitial Lung Disease | February 2007 | July 2010 |
| NCT00453713 | Completed | Race, Ethnicity, and Diffuse Parenchymal Lung Disease | July 2006 | August 2013 | |
| NCT00463983 | Completed | Phase 1/Phase 2 | Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide | October 2006 | January 2012 |
| NCT00071461 | Completed | Phase 2/Phase 3 | Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis | August 2003 | May 2010 |
| NCT00512967 | Completed | The Occurence of Inflammation and Oxidative Stress in Lung Diseases | September 2005 | June 2006 | |
| NCT00532233 | Completed | Phase 2 | SD, IL-13 Production Rate in IPF | September 2007 | June 2009 |
| NCT00540475 | Completed | Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry | September 2007 | July 2018 | |
| NCT00600028 | Completed | Phase 3 | Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide | December 2007 | September 2011 |
| NCT00631475 | Completed | Phase 3 | Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 | April 2008 | May 2010 |
| NCT00662038 | Completed | Phase 3 | Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) | August 2008 | February 2016 |
| NCT04525547 | Completed | Safety and Effectiveness of Nintedanib in Korean Patients | January 13, 2021 | August 18, 2022 | |
| NCT03725852 | Completed | Phase 2 | A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) | September 27, 2018 | August 14, 2020 |
| NCT03727802 | Completed | Phase 1 | Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis | November 28, 2018 | April 1, 2022 |
| NCT03732859 | Completed | PROOF-Registry New and Extended Belgium -Luxembourg | January 9, 2018 | January 9, 2022 | |
| NCT04512170 | Completed | Phase 1 | Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects | July 13, 2020 | August 23, 2021 |
| NCT04481074 | Completed | N/A | Inspiratory Muscle Training in Patients With Interstitial Lung Disease | July 30, 2020 | April 30, 2021 |
| NCT03761082 | Completed | Post Marketing Surveillance of PIRESPA® TAB 200mg (Pirfenidone) for Evaluating the Safety and Efficacy | July 2014 | April 2017 | |
| NCT03770845 | Completed | Nutritional Assessment in Idiopathic Pulmonary Fibrosis | December 10, 2018 | September 1, 2021 | |
| NCT04430491 | Completed | To Evaluate the Use of Radiomics to Classify Between Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease | January 1, 2005 | July 1, 2017 | |
| NCT03830125 | Completed | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects | February 13, 2019 | November 24, 2019 |
| NCT03890250 | Completed | N/A | Neuromuscular Electrical Stimulation in Patients With Idiopathic Pulmonary Fibrosis | March 20, 2019 | January 1, 2024 |
| NCT03898284 | Completed | Impulse Oscillometry for Prognostication in Idiopathic Pulmonary Fibrosis | April 23, 2019 | September 27, 2021 | |
| NCT00262405 | Completed | Phase 2 | Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis | January 2001 | May 2007 |
| NCT03928847 | Completed | Early Phase 1 | Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. | December 1, 2017 | May 31, 2019 |
| NCT03944928 | Completed | ThOracic Ultrasound in Idiopathic Pulmonary Fibrosis Evolution | June 11, 2019 | September 9, 2021 | |
| NCT04429516 | Completed | Phase 3 | Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough | December 17, 2020 | March 21, 2023 |
| NCT04419506 | Completed | Phase 2 | A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) | July 28, 2020 | October 15, 2021 |
| NCT03958071 | Completed | A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking | February 1, 2019 | May 31, 2019 | |
| NCT03979430 | Completed | N/A | Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study | September 7, 2018 | December 31, 2020 |
| NCT03979703 | Completed | N/A | Yoga in Patients With Fibrosing Interstitial Lung Diseases | December 1, 2018 | May 31, 2020 |
| NCT03981406 | Completed | N/A | Palliative Care and Quality of Life in Idiopathic Pulmonary Fibrosis | September 15, 2017 | March 1, 2019 |
| NCT02248064 | Completed | N/A | Auto-titrating Oxygen in Chronic Respiratory Failure | July 2014 | November 2015 |
| NCT02257177 | Completed | Phase 1/Phase 2 | RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients | September 2014 | December 2016 |
| NCT02267655 | Completed | Phase 1 | 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF | May 2015 | June 28, 2017 |
| NCT02268981 | Completed | N/A | Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) | September 2014 | September 2015 |
| NCT02315586 | Completed | Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis | January 28, 2015 | February 23, 2022 | |
| NCT02345070 | Completed | Phase 2 | Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis | May 1, 2015 | August 14, 2017 |
| NCT05173571 | Completed | N/A | Homecare Integral Support Program for IPF Patients | July 1, 2018 | December 12, 2021 |
| NCT02436278 | Completed | The Predictive Ability of 4MGS in IPF | March 2015 | October 20, 2017 | |
| NCT02437448 | Completed | Breath Analysis in Lung Fibrosis | June 2015 | December 2018 | |
| NCT02445157 | Completed | Reliability of the 4 Metre Gait Speed in Idiopathic Pulmonary Fibrosis | February 2015 | August 2015 | |
| NCT02460588 | Completed | Phase 3 | Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis | December 2015 | July 2019 |
| NCT02477709 | Completed | Phase 2 | A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | July 20, 2015 | August 21, 2015 |
| NCT02478268 | Completed | Phase 1 | Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis | May 2015 | September 26, 2020 |
| NCT05154240 | Completed | Phase 1 | A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects | February 21, 2022 | December 2, 2022 |
| NCT02502097 | Completed | Phase 2 | A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016) | August 26, 2015 | July 14, 2016 |
| NCT02503657 | Completed | Phase 2 | Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | March 9, 2016 | March 15, 2022 |
| NCT02530736 | Completed | Responsiveness and MID of 4 Metre Gait Speed in Idiopathic Pulmonary Fibrosis | February 2015 | October 18, 2017 | |
| NCT02550873 | Completed | Phase 2 | A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | September 1, 2015 | May 2, 2017 |
| NCT00047645 | Completed | Phase 3 | A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF) | April 2000 | December 2002 |
| NCT02552849 | Completed | Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada | April 25, 2013 | August 15, 2017 | |
| NCT02579603 | Completed | Phase 4 | Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF | October 16, 2015 | January 31, 2017 |
| NCT02594839 | Completed | Phase 1/Phase 2 | Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease | February 2013 | January 2018 |
| NCT02598193 | Completed | Phase 4 | Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF) | January 14, 2016 | May 16, 2017 |
| NCT02600689 | Completed | N/A | Home-Based Pulmonary Rehab for Patients With Pulmonary Fibrosis | August 2015 | March 16, 2018 |
| NCT02606877 | Completed | Phase 4 | A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination | April 19, 2016 | March 22, 2017 |
| NCT02607722 | Completed | All-Case Surveillance of Ofev in Patients With IPF in Japan | August 31, 2015 | May 2, 2023 | |
| NCT02612051 | Completed | Phase 1 | First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients | December 4, 2015 | June 2, 2016 |
| NCT02622477 | Completed | Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone) | June 2014 | December 2016 | |
| NCT02630940 | Completed | Exhaled Breath Condensate Biomarkers and Cough in IPF | January 2016 | June 2016 | |
| NCT02648048 | Completed | Phase 1 | A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis | January 15, 2016 | November 30, 2016 |
| NCT02688647 | Completed | Phase 2 | A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis | May 26, 2016 | April 13, 2021 |
| NCT02699879 | Completed | Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF) | February 16, 2012 | September 15, 2016 | |
| NCT02707640 | Completed | Phase 2 | A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF) | August 2013 | February 2015 |
| NCT02738801 | Completed | Phase 2 | Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | March 2016 | May 2, 2017 |
| NCT02739165 | Completed | Phase 3 | Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis | May 2016 | December 2018 |
| NCT02745184 | Completed | Phase 1/Phase 2 | Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis | March 30, 2017 | August 31, 2020 |
| NCT05134727 | Completed | Phase 1 | Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants | November 18, 2021 | March 31, 2023 |
| NCT02788474 | Completed | Phase 4 | Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment | June 9, 2016 | June 8, 2018 |
| NCT02802345 | Completed | Phase 3 | Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment | June 30, 2016 | April 13, 2018 |
| NCT02803580 | Completed | IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis | November 17, 2015 | May 15, 2018 | |
| NCT02818712 | Completed | Health-related Quality of Life and Comorbidities in Danish Patients With Idiopathic Pulmonary Fibrosis - a Nationwide Follow-up | August 2016 | June 2021 | |
| NCT05130970 | Completed | Phase 2 | CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis | January 27, 2022 | January 2, 2024 |
| NCT05113654 | Completed | Sleep Disorders in Idiopathic Pulmonary Fibrosis | April 26, 2016 | June 7, 2019 | |
| NCT02846324 | Completed | Phase 2 | Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF | June 2016 | November 2017 |
| NCT05095363 | Completed | N/A | Palliative Care Planner (PCplanner) | March 16, 2022 | March 31, 2023 |
| NCT02871401 | Completed | Phase 1 | A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF) | January 3, 2018 | January 31, 2020 |
| NCT02929017 | Completed | N/A | Integrating Palliative Care for Patients With Idiopathic Pulmonary Fibrosis and Their Caregivers | March 23, 2017 | June 24, 2020 |
| NCT02951429 | Completed | Phase 2 | Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension | December 31, 2016 | August 22, 2020 |
| NCT03047031 | Completed | Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis | April 5, 2017 | July 21, 2022 | |
| NCT05022784 | Completed | Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients | August 23, 2021 | December 30, 2021 | |
| NCT03074149 | Completed | Investigating Idiopathic Pulmonary Fibrosis in Greece | April 4, 2017 | March 30, 2021 | |
| NCT03078426 | Completed | N/A | Lung MRI in the Management of Idiopathic Pulmonary Fibrosis | February 16, 2017 | February 14, 2020 |
| NCT03092102 | Completed | Phase 1 | The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects | May 20, 2017 | February 25, 2019 |
| NCT03104322 | Completed | N/A | Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis | June 15, 2017 | March 9, 2018 |
| NCT03115619 | Completed | Quality of Life Study in Participants With IPF Under Pirfenidone Treatment | April 18, 2017 | January 10, 2020 | |
| NCT00080223 | Completed | Phase 2 | Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis | August 31, 2003 | April 30, 2015 |
| NCT05022771 | Completed | Phase 1 | A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015 | October 14, 2021 | August 18, 2022 |
| NCT04986540 | Completed | Phase 1 | A Trial of SHR - 1906 in Healthy Subjects | August 10, 2021 | September 7, 2022 |
| NCT00105183 | Completed | Phase 3 | EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection | January 2005 | January 2011 |
| NCT03208933 | Completed | Phase 3 | Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). | October 23, 2017 | November 13, 2019 |
| NCT03211507 | Completed | Idiopathic Pulmonary Fibrosis Job Exposures Study | May 1, 2017 | October 5, 2019 | |
| NCT04968574 | Completed | Phase 2 | A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | August 26, 2021 | November 30, 2023 |
| NCT03222648 | Completed | N/A | Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis | September 22, 2017 | August 8, 2023 |
| NCT04931147 | Completed | Phase 1 | A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers | May 13, 2021 | March 8, 2023 |
| NCT03261037 | Completed | N/A | A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period | December 25, 2017 | November 27, 2019 |
| NCT03268915 | Completed | N/A | Idiopathic Pulmonary Fibrosis (IPF) and the 3 Minutes Sit-to-stand Test | February 9, 2017 | December 9, 2018 |
| NCT03281200 | Completed | Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain | October 24, 2017 | June 7, 2018 | |
| NCT04888728 | Completed | Phase 1 | To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers | June 30, 2021 | July 27, 2021 |
| NCT03300583 | Completed | Toward Self-management in ILD | June 1, 2018 | December 30, 2020 | |
| NCT03326089 | Completed | N/A | Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis | June 1, 2017 | August 28, 2023 |
| NCT04888715 | Completed | Phase 1 | To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers | July 23, 2021 | August 18, 2021 |
| NCT03386994 | Completed | OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study | November 29, 2017 | September 16, 2019 | |
| NCT03411876 | Completed | N/A | Effects of Oxymizer Pendant Cannula Versus Conventional Nasal Cannula During Endurance Shuttle Walk Tests in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis | January 18, 2018 | January 15, 2019 |
| NCT03420235 | Completed | N/A | Home Monitoring in Idiopathic Pulmonary Fibrosis; Improving Use of Anti-fibrotic Medication and Quality of Life | January 9, 2018 | August 26, 2019 |
| NCT03422068 | Completed | Phase 1 | This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated. | March 16, 2018 | July 10, 2019 |
| NCT00125385 | Completed | Phase 1 | Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | July 2005 | September 2008 |
| NCT04803617 | Completed | Investigation of Pectoralis Muscle Strength in Elderly With Interstitial Lung Disease | January 23, 2017 | June 23, 2017 | |
| NCT03499275 | Completed | N/A | Muscle Stimulation in Advanced Idiopathic Pulmonary Fibrosis | October 15, 2018 | August 15, 2020 |
| NCT00131274 | Completed | Phase 2/Phase 3 | Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study | April 2003 | August 2007 |
| NCT03502902 | Completed | Phase 1 | The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects | April 26, 2018 | March 15, 2019 |
| NCT03503188 | Completed | Phase 4 | Digital Auscultation Test - IPF Data Collection | March 28, 2018 | January 3, 2019 |
| NCT03538301 | Completed | Phase 2 | JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF | June 18, 2018 | August 24, 2022 |
| NCT04775277 | Completed | Outcome of Idiopathic Pulmonary Fibrosis With Pregnancy | December 1, 2018 | February 20, 2021 | |
| NCT04767815 | Completed | Phase 1 | To Evaluate Food Effect on the PK and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers | March 22, 2021 | June 4, 2021 |
| NCT04720443 | Completed | Phase 1 | A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects | November 22, 2019 | July 14, 2022 |
| NCT03567785 | Completed | Supporting Adherence to Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | July 17, 2018 | February 11, 2021 | |
| NCT03588260 | Completed | Respiratory Muscle Strength in Patients With Idiopathic Pulmonary Fibrosis | July 20, 2018 | December 30, 2023 | |
| NCT04586946 | Completed | FIBRotic Interstitial Lung Disease and Nocturnal OXygen | December 17, 2018 | May 30, 2021 | |
| NCT03641742 | Completed | Families-At-risk for Interstitial Lung Disease Study | January 15, 2018 | July 1, 2023 | |
| NCT04572971 | Completed | Reliability and Validity of iOS in IPF | November 6, 2020 | March 30, 2022 | |
| NCT04564664 | Completed | N/A | High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis | March 1, 2019 | March 30, 2021 |
| NCT00189176 | Completed | Phase 1/Phase 2 | Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis | March 2003 | May 2006 |
| NCT03710824 | Completed | Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib | February 28, 2019 | February 22, 2023 | |
| NCT04533022 | Completed | Phase 2 | Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF | November 13, 2020 | March 30, 2024 |
| NCT03711435 | Completed | Traditional Chinese Medicine(TCM) Syndrome Classification of Idiopathic Pulmonary Fibrosis(IPF) and Metabolomics | October 20, 2018 | February 5, 2020 | |
| NCT04016181 | Enrolling by invitation | The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study | June 14, 2007 | December 1, 2036 | |
| NCT04326036 | Enrolling by invitation | Early Phase 1 | Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection | March 25, 2020 | January 31, 2024 |
| NCT04896138 | Enrolling by invitation | University of Virginia Natural History Study | August 28, 2018 | August 31, 2035 | |
| NCT04905693 | Enrolling by invitation | Phase 3 | Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | September 6, 2022 | June 2026 |
| NCT02230982 | No longer available | Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis | |||
| NCT05983471 | Not yet recruiting | Phase 2 | Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF) | November 2023 | March 2025 |
| NCT06238622 | Not yet recruiting | Phase 3 | A Follow-up Study to Test Long-term Treatment With BI 1015550 in People With Pulmonary Fibrosis Who Took Part in a Previous Study With BI 1015550 | July 1, 2024 | May 5, 2027 |
| NCT05988463 | Not yet recruiting | Phase 1 | Open-Label Dose-Escalation Treatment Study of Patients With IPF | February 1, 2024 | November 1, 2024 |
| NCT06325696 | Not yet recruiting | Phase 2 | H01 in Adults With Interstitial Lung Disease (The SOLIS Study) | June 23, 2024 | December 31, 2025 |
| NCT05842681 | Not yet recruiting | N/A | Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis | June 1, 2023 | June 1, 2024 |
| NCT06317285 | Not yet recruiting | Phase 2 | A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) | April 1, 2024 | March 19, 2026 |
| NCT06335303 | Not yet recruiting | Phase 2 | A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) | July 24, 2024 | July 21, 2026 |
| NCT06323876 | Not yet recruiting | The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis | May 2024 | May 2029 | |
| NCT06422884 | Not yet recruiting | Phase 2 | A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) | September 2024 | June 2026 |
| NCT06360094 | Not yet recruiting | Phase 2 | A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis | July 27, 2024 | August 6, 2025 |
| NCT05424887 | Not yet recruiting | Phase 2 | A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis | July 2022 | October 2024 |
| NCT06049004 | Not yet recruiting | Londrina Activities of Daily Living Protocol in Idiopathic Pulmonary Fibrosis Patients | November 1, 2023 | November 1, 2024 | |
| NCT05755308 | Not yet recruiting | N/A | Faecal Microbiota Transplantation to Ameliorate Nintedanib-induced Diarrhea in Patients With Idiopathic Pulmonary Fibrosis | October 2023 | April 2026 |
| NCT03800017 | Not yet recruiting | N/A | Skeletal Muscle Function in Interstitial Lung Disease | June 1, 2024 | December 31, 2026 |
| NCT06102083 | Not yet recruiting | Phase 2 | A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis | November 2, 2023 | March 1, 2026 |
| NCT06241560 | Not yet recruiting | Phase 2 | A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood | September 30, 2024 | August 15, 2025 |
| NCT06445686 | Recruiting | Ongoing Monitoring of Vital Signs in Patients With Idiopathic Pulmonary Fibrosis Before and After Acute Exacerbation. | June 2024 | February 2026 | |
| NCT00373841 | Recruiting | Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF) | October 2005 | July 2030 | |
| NCT00470327 | Recruiting | A Study of the Natural Progression of Interstitial Lung Disease (ILD) | September 2005 | December 2025 | |
| NCT01088217 | Recruiting | Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF) | July 2008 | June 2025 | |
| NCT02551068 | Recruiting | N/A | High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib | December 2015 | April 2025 |
| NCT02632123 | Recruiting | Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis | December 2015 | December 2025 | |
| NCT03120481 | Recruiting | Controls for Respiratory Diseases | April 10, 2017 | February 28, 2037 | |
| NCT03183570 | Recruiting | Early Phase 1 | Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT | November 8, 2017 | April 14, 2025 |
| NCT03437486 | Recruiting | Mechanisms of Familial Pulmonary Fibrosis | January 1, 2009 | April 30, 2025 | |
| NCT03500731 | Recruiting | Phase 1/Phase 2 | Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure | April 19, 2018 | December 2026 |
| NCT03692481 | Recruiting | N/A | Evolution of Lung 18FDG Uptake in Patients With Idiopathic Pulmonary Fibrosis and Receiving Pirfenidone | February 4, 2020 | April 2024 |
| NCT03836417 | Recruiting | Molecular Diagnosis of Idiopathic Interstitial Pneumonias: a Prospective Study | June 28, 2019 | June 30, 2025 | |
| NCT03865927 | Recruiting | Phase 2 | GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis | September 7, 2020 | January 1, 2025 |
| NCT03901196 | Recruiting | Multi-elemental Imaging of Lung Tissues With LIBS (Laser-induced Breakdown Spectroscopy) | January 22, 2020 | January 22, 2025 | |
| NCT04160715 | Recruiting | Korean Idiopathic Pulmonary Fibrosis Registry | January 2016 | December 2026 | |
| NCT04187690 | Recruiting | N/A | Jin-shui Huan-xian Granule in the Treatment of IPF | September 1, 2020 | July 30, 2023 |
| NCT04263727 | Recruiting | A Study of Patients With Chronic Disease | February 27, 2020 | February 2035 | |
| NCT04268485 | Recruiting | Longitudinal Changes in Serum KL-6 in IPF | February 1, 2021 | December 30, 2024 | |
| NCT04362644 | Recruiting | Phase 1 | Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis | December 8, 2020 | June 1, 2025 |
| NCT04442711 | Recruiting | Cohort of IPF Patients Experiencing an Exacerbation | June 13, 2020 | December 31, 2028 | |
| NCT04540770 | Recruiting | Phase 1 | A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001 | August 31, 2021 | December 31, 2023 |
| NCT04619199 | Recruiting | N/A | Influence of Socioeconomic and Environmental Factors on the Natural History of Idiopathic Pulmonary Fibrosis | April 1, 2021 | April 1, 2025 |
| NCT04708782 | Recruiting | Phase 3 | Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | June 1, 2021 | June 2025 |
| NCT04838275 | Recruiting | N/A | IPF mHealth Exercise | April 1, 2021 | December 31, 2023 |
| NCT04965298 | Recruiting | Phase 3 | Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole | June 16, 2021 | February 28, 2025 |
| NCT05016817 | Recruiting | Phase 1 | Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF | July 3, 2022 | September 2025 |
| NCT05042219 | Recruiting | Effects of Pulmonary Diseases and Their Treatment on Cardiac Function | June 1, 2022 | September 14, 2024 | |
| NCT05052229 | Recruiting | Early Phase 1 | Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF). | April 21, 2022 | February 28, 2025 |
| NCT05060822 | Recruiting | Phase 2 | Phase ll Study of HEC585 in Patients With IPF | June 30, 2021 | May 11, 2025 |
| NCT05098717 | Recruiting | End-expiratory Trans-pulmonary Pressure Guided PEEP Titration in Patients With Pulmonary Fibrosis and UIP Pattern Undergoing Mechanical Ventilation | February 8, 2023 | January 1, 2027 | |
| NCT05195918 | Recruiting | Phase 1 | Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients | August 24, 2023 | March 31, 2025 |
| NCT05241275 | Recruiting | Phase 2 | Xenon MRI and Progressive ILD | July 19, 2022 | June 1, 2026 |
| NCT05255991 | Recruiting | Phase 3 | Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | October 4, 2022 | June 2025 |
| NCT05331729 | Recruiting | Phase 1 | Evaluation of the Value of 18F-Fluoromisonidazole (18F-FMISO) Positron Emission Tomography Hypoxia Imaging in Idiopathic Pulmonary Fibrosis | March 20, 2023 | May 2026 |
| NCT05359965 | Recruiting | N/A | Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF | October 1, 2019 | March 1, 2025 |
| NCT05366387 | Recruiting | N/A | Effect of Intrapulmonary Percussion Ventilation on Deposition of Inhaled Aerosols in Idiopathic Pulmonary Fibrosis | November 23, 2022 | May 2024 |
| NCT05382572 | Recruiting | Pulmonary Fibrosis Foundation Community Registry | July 11, 2022 | July 1, 2025 | |
| NCT05389215 | Recruiting | Phase 2 | Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF | July 29, 2022 | December 19, 2025 |
| NCT05392881 | Recruiting | Interstitial Lung Disease Research Unit Biobank | August 9, 2021 | March 1, 2032 | |
| NCT05449431 | Recruiting | N/A | Comparison of the 1-min Sit-to-Stand Test to the 6-minute Walk Test in the Respiratory Functional Assessment of Pulmonary Fibrosis | August 8, 2022 | December 5, 2024 |
| NCT05468502 | Recruiting | Phase 1 | Phase I/IIa Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF) | October 10, 2022 | August 2025 |
| NCT05483907 | Recruiting | Phase 2 | To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF | April 12, 2023 | December 31, 2024 |
| NCT05515627 | Recruiting | Phase 1 | Atezolizumab for Idiopathic Pulmonary Fibrosis | February 15, 2023 | April 30, 2026 |
| NCT05537025 | Recruiting | Phase 1/Phase 2 | Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis | January 30, 2023 | March 2025 |
| NCT05571059 | Recruiting | Phase 2 | Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) | January 31, 2024 | January 2026 |
| NCT05671835 | Recruiting | Phase 2 | Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis | May 15, 2023 | March 2025 |
| NCT05722964 | Recruiting | Phase 2 | Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis | March 29, 2023 | May 31, 2024 |
| NCT05785624 | Recruiting | Phase 2 | A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease | May 26, 2023 | August 10, 2027 |
| NCT05863091 | Recruiting | N/A | Respiratory Rate Validation Study - HiCardi+ Wearable Patch Device, Mezoo Co., Ltd. | March 9, 2023 | June 2023 |
| NCT05883293 | Recruiting | Early Phase 1 | Clinical Study of Allogeneic Adipovarian Active Protein in the Treatment of Severe Idiopathic Pulmonary Fibrosis | June 1, 2023 | December 31, 2024 |
| NCT05912049 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects | July 26, 2023 | December 2023 |
| NCT05951296 | Recruiting | Phase 2 | A Study to Investigate Leramistat in Patients With IPF | August 30, 2023 | September 2024 |
| NCT05954988 | Recruiting | Phase 1 | A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients | July 6, 2023 | January 2024 |
| NCT05964335 | Recruiting | Phase 2 | Cough Reduction in IPF With Nalbuphine ER | February 6, 2024 | October 14, 2024 |
| NCT05989698 | Recruiting | N/A | C-mo System 1.0's Validation - Cough Monitoring | December 11, 2023 | June 11, 2025 |
| NCT06003426 | Recruiting | Phase 3 | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | September 14, 2023 | October 26, 2026 |
| NCT06027372 | Recruiting | Heart Rate Variability and Nocturnal Blood Oxygen Saturation in Patients With Idiopathic Pulmonary Fibrosis | May 21, 2020 | June 30, 2024 | |
| NCT06037408 | Recruiting | Phase 3 | The Effect of N115 on Coughing in IPF Patients | August 15, 2023 | August 31, 2024 |
| NCT06081621 | Recruiting | Phase 2 | A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF) | June 30, 2023 | July 2025 |
| NCT06097260 | Recruiting | Phase 2 | Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis | November 16, 2023 | September 30, 2025 |
| NCT06125327 | Recruiting | Phase 2/Phase 3 | SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | June 6, 2023 | December 31, 2025 |
| NCT06132256 | Recruiting | Phase 2 | Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | December 11, 2023 | June 2025 |
| NCT06189820 | Recruiting | Phase 2 | Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases | March 9, 2023 | March 9, 2027 |
| NCT06200714 | Recruiting | A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib | April 30, 2024 | April 30, 2025 | |
| NCT06230822 | Recruiting | Phase 1 | Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF) | February 2024 | December 2026 |
| NCT06265532 | Recruiting | Phase 1 | Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect | February 7, 2024 | May 31, 2025 |
| NCT06267183 | Recruiting | Early Phase 1 | A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers. | January 12, 2024 | March 30, 2025 |
| NCT06331624 | Recruiting | Phase 2 | Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF | March 2024 | January 2025 |
| NCT00075998 | Terminated | Phase 3 | The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) | December 2003 | May 2007 |
| NCT02052297 | Terminated | Phase 1 | A Validation and Dosimetry Study of GSK2634673F PET Ligand | January 24, 2014 | April 21, 2016 |
| NCT03955146 | Terminated | Phase 3 | Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | June 18, 2019 | August 28, 2023 |
| NCT04419558 | Terminated | Phase 3 | Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | September 30, 2020 | September 4, 2023 |
| NCT03949530 | Terminated | Phase 1 | A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis | April 16, 2019 | March 29, 2020 |
| NCT00957242 | Terminated | Phase 3 | AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis | October 2009 | July 2011 |
| NCT03480451 | Terminated | N/A | Targeted Intervention for Patient Centered Outcome in Patients With Idiopathic Pulmonary Fibrosis | September 12, 2017 | February 1, 2019 |
| NCT03744598 | Terminated | Self-monitoring of Spirometry & Symptoms Via patientMpower App in Idiopathic Pulmonary Fibrosis | November 28, 2018 | April 30, 2020 | |
| NCT03562247 | Terminated | N/A | Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF) | August 1, 2018 | May 26, 2020 |
| NCT03733444 | Terminated | Phase 3 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care | November 5, 2018 | March 30, 2021 |
| NCT03717012 | Terminated | Phase 4 | Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF) | November 15, 2018 | June 10, 2020 |
| NCT03711162 | Terminated | Phase 3 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care | November 28, 2018 | March 30, 2021 |
| NCT00703339 | Terminated | Phase 2 | Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis | June 2008 | December 2009 |
| NCT01629667 | Terminated | Phase 2 | A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis | October 2012 | January 2016 |
| NCT04552899 | Terminated | Phase 3 | A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis | March 19, 2021 | February 10, 2023 |
| NCT03274544 | Terminated | N/A | Clinical Trial of Chinese Herbal Medicine for Idiopathic Pulmonary Fibrosis (IPF) | August 14, 2018 | June 1, 2020 |
| NCT02989168 | Terminated | Phase 2 | Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest | November 2016 | October 23, 2017 |
| NCT00768300 | Terminated | Phase 3 | (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF | December 2008 | February 2011 |
| NCT03562416 | Terminated | Phase 2 | Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects | July 5, 2019 | December 21, 2021 |
| NCT04594707 | Terminated | Phase 3 | A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis | August 30, 2021 | February 10, 2023 |
| NCT03573505 | Terminated | Phase 2 | An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis | September 24, 2018 | November 14, 2019 |
| NCT01841307 | Terminated | Phase 1 | Cromolyn Detection of Silent Aspiration | July 2015 | September 2017 |
| NCT03069989 | Terminated | Phase 1 | Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging | June 13, 2017 | July 18, 2018 |
| NCT01266135 | Terminated | Phase 2 | Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | December 2010 | April 2013 |
| NCT00076635 | Terminated | Phase 3 | An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF | November 2003 | April 2007 |
| NCT01777737 | Terminated | Phase 3 | Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole | November 25, 2013 | November 5, 2015 |
| NCT01769196 | Terminated | Phase 2 | Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) | January 31, 2013 | February 23, 2016 |
| NCT01203943 | Terminated | Phase 2 | A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF) | January 1, 2011 | August 24, 2012 |
| NCT01321996 | Terminated | Phase 4 | 68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis | February 2009 | December 2013 |
| NCT00981747 | Terminated | Phase 2/Phase 3 | Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis | September 2009 | December 2016 |
| NCT01759511 | Terminated | Phase 2 | Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF) | October 18, 2012 | February 19, 2016 |
| NCT02821039 | Terminated | Turkish Thoracic Society Usual Interstitial Pneumonia Registry Study | June 2016 | July 8, 2019 | |
| NCT03142191 | Terminated | Phase 2 | A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis | July 26, 2017 | December 24, 2021 |
| NCT03287414 | Terminated | Phase 2 | Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis | December 20, 2017 | February 14, 2022 |
| NCT02759120 | Terminated | Phase 3 | CleanUP IPF for the Pulmonary Trials Cooperative | March 22, 2017 | March 16, 2020 |
| NCT00879229 | Terminated | Phase 3 | ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis | July 2009 | February 2011 |
| NCT01499745 | Unknown status | N/A | Exercise Training at Ambulatory Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis Patients | January 2012 | December 2013 |
| NCT02848625 | Unknown status | N/A | Yoga Effect on Quality of Life Study Among Patients With Idiopathic Pulmonary Fibrosis | August 2016 | April 2018 |
| NCT01382368 | Unknown status | Phase 4 | Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients | September 2011 | September 2013 |
| NCT02827734 | Unknown status | Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD) | October 2015 | December 2020 | |
| NCT02485886 | Unknown status | Early Phase 1 | 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis | January 2015 | December 2017 |
| NCT02397005 | Unknown status | Phase 1 | Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects | March 2015 | August 2019 |
| NCT02176707 | Unknown status | Modelling of Quality Life, Clinical and Physiological Measures in Idiopathic Pulmonary Fibrosis | June 2014 | February 2017 | |
| NCT02135380 | Unknown status | Phase 1/Phase 2 | Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis | August 2014 | |
| NCT05373914 | Unknown status | Phase 2 | RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) | May 31, 2022 | March 31, 2024 |
| NCT00518310 | Unknown status | N/A | Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis | May 2005 | December 2008 |
| NCT01809574 | Unknown status | The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease | May 2013 | March 2016 | |
| NCT01154998 | Unknown status | Case-Control Study of Fibrotic Interstitial Lung Disease (ILD) and Cardiac Disease / Interventions. | July 2010 | April 2011 | |
| NCT01738711 | Unknown status | N/A | Does CBT Improve the Perception/Impact of Cough and Breathlessness in IPF Patients | December 2012 | February 2014 |
| NCT04257630 | Unknown status | Coping Strategies Within Pulmonary Rehabilitation in Patients With IPF and COPD | February 6, 2020 | March 31, 2022 | |
| NCT04197791 | Unknown status | N/A | Effect of Core Stabilization Exercises and Neuromuscular Electrical Stimulation in Patients With Idiopathic Pulmonary Fibrosis | December 10, 2019 | December 2020 |
| NCT04148157 | Unknown status | Quality of Life in IPF - Patient and Physician Perceptions | September 23, 2019 | July 1, 2020 | |
| NCT04019080 | Unknown status | Real-Life Use of Anti-fibrotic Drugs in Patients With Idiopathic Pulmonary Fibrosis in Sweden | January 1, 2019 | December 2021 | |
| NCT03813810 | Unknown status | Impact of Air Pollution on Chronic Respiratory Diseases | January 25, 2019 | December 2021 | |
| NCT03688334 | Unknown status | N/A | Acute Effects of Oxygen Supplementation Among IPF Patients | June 1, 2018 | June 1, 2019 |
| NCT03670576 | Unknown status | It's Not JUST Idiopathic Pulmonary Fibrosis Study | November 11, 2018 | November 11, 2022 | |
| NCT03666234 | Unknown status | Idiopathic Pulmonary Fibrosis Registry China Study | July 1, 2018 | June 30, 2023 | |
| NCT01714934 | Unknown status | The Role of Gastric Content Microaspirations in the Pathogenesis of Idiopathic Pulmonary Fibrosis | January 2013 | December 2014 | |
| NCT04693975 | Unknown status | Social Distancing During the COVID-19 Pandemic and People Living With Chronic Respiratory Diseases | October 16, 2020 | October 2022 | |
| NCT03560154 | Unknown status | N/A | Effects of Whole Body Vibration Training in Patients With Interstitial Lung Disease | January 2017 | September 2020 |
| NCT03548181 | Unknown status | Phase 2 | Feasibility & Effect of a Tele-rehabilitation Program in Idiopathic Pulmonary Fibrosis (IPF) | September 1, 2017 | January 31, 2020 |
| NCT00637065 | Unknown status | Phase 4 | Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study | April 2008 | August 2010 |
| NCT03360032 | Unknown status | Comparing Measurements Made in an Incremental Shuttle Walk Test and a Cardiopulmonary Exercise Test in Patients With IPF | January 10, 2018 | April 2020 | |
| NCT03229343 | Unknown status | N/A | Impact of a Systematic Palliative Care on Quality of Life, in Advanced Idiopathic Pulmonary Fibrosis. | December 4, 2017 | February 2021 |
| NCT03215147 | Unknown status | Prevalence and Impact on Quality of Life of Airway Disease in Patients With Idiopathic Pulmonary Fibrosis | June 7, 2017 | February 28, 2020 | |
| NCT03171870 | Unknown status | N/A | Characteristics and Health Related Quality of Life in Idiopathic Pulmonary Fibrosis | June 2017 | June 2018 |
| NCT02885961 | Unknown status | N/A | The Coagulation Cascade in Idiopathic Pulmonary Fibrosis | August 2016 | |
| NCT01504334 | Unknown status | Phase 2 | Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF) | January 2012 | March 2013 |
| NCT00203697 | Unknown status | Phase 3 | Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study | ||
| NCT00625079 | Withdrawn | Phase 4 | Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil | February 2007 | December 2009 |
| NCT03258801 | Withdrawn | Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis | October 29, 2018 | December 2, 2019 | |
| NCT03591926 | Withdrawn | Phase 2 | A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | January 1900 | January 1900 |
| NCT04677426 | Withdrawn | Phase 2 | 129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study | May 1, 2022 | August 1, 2022 |
| NCT02168530 | Withdrawn | Phase 2 | A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) | October 2014 | January 2017 |
| NCT04541875 | Withdrawn | Medication Adherence and Non-adherence in Adults With Rare Disease | January 2021 | September 2022 | |
| NCT04494334 | Withdrawn | Development of Airway Absorption Sampling Methods | January 1, 2022 | January 1, 2022 | |
| NCT00625469 | Withdrawn | Phase 4 | Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan | October 2007 | December 2009 |
| NCT01346930 | Withdrawn | Phase 2 | Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis | July 2011 | August 2016 |
| NCT00212511 | Withdrawn | Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry | November 2004 | January 2018 | |
| NCT02187393 | Withdrawn | Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis | July 2015 | November 2015 | |
| NCT01524068 | Withdrawn | Phase 2 | A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations | September 2012 | June 2016 |
| NCT04244825 | Withdrawn | Phase 2 | Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF | December 15, 2019 | November 5, 2020 |
- OrphaNumber from OrphaNet (Orphanet)
- 2032
- MedGen concept unique identifier (MedGen Concept name)
- C0085786
- MedGen unique identifier (MedGen Concept name)
- 39340
- MeSH unique ID (MeSH (Medical Subject Headings))
- D054990